GENITOURINARY

CHELSEA HOTEL, TORONTO, ON

ROOM: WREN

SATURDAY APRIL 28TH, 2018, 8:00 AM – 3:00 PM

CHAIR: K. CHI

SENIOR INVESTIGATOR: FRANCISCO VERA-BADILLO

STUDY COORDINATORS: ALEXANDER MONTENEGRO & PAUL STOS

(03:00 PM – 04:00 PM TRIAL DEVELOPMENT GROUP – CLOSED)

Learning Objectives:

− To interpret and address, through clinical and translational research, the disease burden associated with genitourinary malignancies in Canada.
− To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
− To update, review, and discuss recent results of clinical studies conducted by the Canadian Cancer Trials or its collaborators.
− To provide a learning environment supportive to new investigators.
− To interpret and apply new clinical trial methodologies in the field of clinical research in Canada

8:00 am WELCOME K. Chi

8:05 am OPEN CUOG/CURC TRIALS

PRIME N. Usmani

MAST M. Kenk

Hypothermia RCC I. Cagiannos

LIGAND M. Kenk

TITAN K. Chi

ATLAS K. Chi

8:45 am Discussion of opportunities to enhance correlative science activity in CCTG GU trials D. Berman

9:00 am Plenary Presentation: Circulating tumor DNA as a biomarker: opportunities and challenges Dr. Alex Wyatt

CCTG Lead OPEN TRIALS

10:00 am IND.223: A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer K. Chi

IND.232: A Phase II Study of Durvalumab (Medi4736) with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer S. Hotte

continued on next page …
IND.234: Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol

PR.19: A randomized phase II trial evaluating treatment outcome, acute and long-term toxicity of High Dose Rate Brachytherapy (HDRB) and Low Dose Rate Brachytherapy (LDRB) as monotherapy in localized prostate cancer.

Phase II basket trial PM1/CAPTUR (Canadian Profiling and Targeted agent Utilization) S. Hotte

CCTG Lead CLOSED TRIALS
10:25 am BL.12 Phase II Randomized trial of Nab-Paclitaxel vs. Paclitaxel in Second Line Metastatic Urothelial Carcinoma K. Sridhar

CCTG InterGroup OPEN TRIALS
10:40 am REC.3/PAPMET A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors Cabozantinib, Crizotinib and Savolitinib versus Sunitinib in Metastatic Papillary Renal Carcinoma. M. Ong

BLC.4 (SWOG S1605): Phase II Trial of Atezolizumab (NSC #783608) in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. W. Kassouf

CCTG InterGroup CLOSED TRIALS
10:50 am BLC.1/SWOG S1011 Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at the Time Of Radical Cystectomy For Muscle Invasive Urothelial Cancer W. Kassouf

PR.13/RADICALS/MRC PR.10 Radiotherapy and Androgen Deprivation In Combination After Local Surgery W. Parulekar

PRC.4/Alliance A031201 Phase III Enzalutamide + Abiraterone in castration resistant metastatic prostate cancer K. Chi

PR.17/ANZUP 1304- ENZAMET Phase III testosterone suppression with or without Enzalutamide in first line metastatic prostate cancer S. North

PRC.3/CALGB 90203 Neoadjuvant Docetaxel plus Androgen Deprivation prior to RP v.s. RP only K. Chi

continued on next page …
CCTG Approved TRIALS
11:10 am  PNC.1 InPACT: International Penile Advanced Cancer Trial  
J. Crook
PR.20 Phase 3 Trial of Local Ablative Therapy or Not for  
Hormone Sensitive Oligometastatic Prostate Cancer  
P. Cheung/T. Niazi
REC.4 A Phase 3 RandOmized Study Comparing  
PERioperative Nivolumab vs. Observation in Patients  
with Localized Renal Cell Carcinoma Undergoing  
Nephrectomy (PROSPER RCC)  
A. Kapoor
BLC.3 (SWOG S1602): A Randomized Trial to Evaluate the Influence of  
BCG Strain Differences and T Cell Priming with Intradermal BCG  
Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle  
Invasive Bladder Cancer.  
W. Kassouf
BL.13 A Randomized Phase II Trial Assessing Trimodality Therapy  
With Or Without Adjuvant Durvalumab To Treat Patients With  
Muscle-Invasive Bladder Cancer  
W. Kassouf

12:00 pm  LUNCH

New trial proposals
1:30 pm  Concept Title: S1802 “Randomized Trial of Standard Systemic  
Therapy (SST) versus Standard Systemic Therapy plus Definitive  
Treatment (surgery or radiation) of the Primary Tumor in Metastatic  
Prostate Cancer”  
International Rare Cancer Initiative/CRUK Southampton  
S. North
Concept Title: A031702 “Phase II study of Cabozantinib in  
combination with Nivolumab and Ipilimumab in rare genitourinary tumors  
C. Kollmansberger
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of  
accelerated versus standard BEP chemotherapy for patients with  
intermediate and poor-risk metastatic germ cell tumours  
C. Kollmansberger
Darolutamide to Augment Standard Therapy for Localized High-Risk  
Cancer of the Prostate (DASLHiCaP).  
T. Niazi

2:15 pm  GU DSC IDENTIFICATION AND PRIORITIZATION
1. Progress against strategic priorities defined for the CCSRI grant.  
2. Priority tumour and patient populations over the next 3-5 years.  
3. Primary areas of focus for the group in these tumour and patient populations  
over the next 3-5 years in terms of:  
   - treatment modalities  
   - targets  
   - agents

3:00 pm Meeting Adjourned
3:00 pm – 4:00 pm Trial Development Group CLOSED